MDWDNGMHealthcare·Biotechnology#304 in industry

MediWound Ltd.

Reports in 23d· 2026-05-20

-8.1% · 90d

$16.57

-0.15 (-0.90%)

After-Hours $16.57(+0.00)

News

(1)

March 2026

Mar 30, 20260 months ago6-KHealthcare

MediWound Ltd. — 6-K Filing

MDWDMediWound Ltd.

# 🧾 What This Document Is This is a **Notice of Annual General Meeting and Proxy Statement** for MediWound Ltd. In simple terms, it's an official invitation and instruction manual for the company's shareholders. It tells them when and where the yearly meeting is, what decisions need to be voted on,

Read summaryView on SEC EDGAR

Key Data

Market Cap$213.0M

Open$16.57

Prev Close$16.72

Day Range$16.26 – $16.92

52W Range$14.90 – $22.50

Volume31,730

P/E (TTM)—

EPS$-2.10

Dividend Yield—

Beta0.15

Profit Margin-140.80%

Revenue Growth-68.00%

Price Target$31.33(+89.1%)

Next Earnings2026-05-20(23d)

Analyst Ratings

Strong Buy6 analysts

Buy 6Hold 0Sell 0

About

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Healthcare · Biotechnology

121 employees

www.mediwound.com